Current Report Filing (8-k)
October 21 2016 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of Earliest Event Reported): October 21, 2016 (October 20, 2016)
moleculin
biotech, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
|
|
001-37758
|
|
47-4671997
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission File No.)
|
|
(I.R.S. Employer Identification No.)
|
2575
WEST BELLFORT, SUITE 333, HOUSTON TX 77054
(Address of principal executive offices
and zip code)
(713) 300-5160
(Registrant’s telephone number, including
area code)
(Former name or former
address, if changed from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-14(c)).
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
On October 20, 2016,
Moleculin Biotech, Inc. (the “Company”) held a live conference call. In connection with the call, the Company is furnishing
the conference call script attached as Exhibit 99.1 hereto, which is incorporated by reference to this Item 7.01.
The information contained
in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed”
for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein
as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Conference Call Script dated October 20, 2016
|
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|
|
Date: October 21, 2016
|
|
|
|
By:
|
/s/ Jonathan Foster
|
|
|
Jonathan Foster
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
99.1
|
Conference Call Script dated October 20, 2016
|
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024